|
Mutation Information
|
Mutation Site
|
N155D |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
IN |
|
Relevant Drug
|
INSTIs |
|
Country
|
US |
Literature Information
|
PubMed PMID
|
31617907
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2020 |
|
Journal
|
The Journal of antimicrobial chemotherapy |
|
Title
|
Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance. |
|
Author
|
Tzou PL,Rhee SY,Descamps D,Clutter DS,Hare B,Mor O,Grude M,Parkin N,Jordan MR,Bertagnolio S,Schapiro JM,Harrigan PR,Geretti AM,Marcelin AG,Shafer RW,WHO HIVResNet Working Groups. |
|
Evidence
|
Thirty-two additional non-polymorphic mutations that occurred in five or more INSTI-treated persons were significantly selected by INSTI therapy (corrected P value ≤0.05), including four mutations at established INSTI-resistance positions (H51D, E92A, Q95R and N155D) and one mutation (N142T) in the highly conserved catalytic loop extending between positions 140 and 149 (Table 4).
|
|
|
HIV Mutation Detail Information